Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Axsome Therapeutics, Inc. (AXSM)
USD229.57
+1.29 (+0.56%)
US NASDAQ Healthcare Biotechnology
Address
22 Cortlandt Street 10007
New York City, NY, US
New York City, NY, US
CEO
Herriot Tabuteau
Website
axsome.com
IPO
2015-11-19
CIK 1579428 ISIN US05464T1043
Also trades on
London Stock Exchange · 0HKF.L (USD)
NASDAQ Global Market · AXSM (USD)
Description
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
News Sentiment (7d)
3 articles
- Better Growth Buy: Axsome vs Revolution Medicines The Motley Fool
- Axsome Begins Phase III Study on Solriamfetol for ADHD in Children Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD229.57
+1.29 (+0.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
902.8K
Beta
0.60
Float Shares
43.24M
Free Float %
84.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.49% | +1.57% | +25.63% | +23.63% | +63.05% | +22.66% | +112.01% | +188.07% | +273.20% | +2,003.57% | +2,463.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
229.57
Low
200.00
-12.9%
Consensus
255.81
+11.4%
Median
259.50
+13.0%
High
302.00
+31.6%
Ratings Trend (MoM)
95% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 17 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 15 |
266.00
+15.9%
|
| Last Quarter | 25 |
249.04
+8.5%
|
| Last Year | 43 |
231.21
+0.7%
|
| All Time | 70 |
186.84
-18.6%
|
Quality scores
Altman Z-Score
7.93
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+65.6% ★ Q1'26: +57.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+38.6% ★ Q1'26: -3.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-30.9% Q1'26: -10.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-27.7% Q1'26: -33.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-2,661.1% Q1'26: +749.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.8% Q1'26: +4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.44× Q1'26: -0.89× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 13 EPS Ana. |
Dec 2027 17 Rev. Ana. 13 EPS Ana. |
Dec 2028 17 Rev. Ana. 16 EPS Ana. |
Dec 2029 14 Rev. Ana. 14 EPS Ana. |
Dec 2030 8 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
50.04M
est: 46.98M (+6.5%)
|
270.60M
est: 291.49M (-7.2%)
|
385.69M
est: 385.05M (+0.2%)
|
638.50M
est: 635.67M (+0.4%)
|
983.80M
869.18M – 1.12B
+54.8% YoY
|
1.60B
1.21B – 1.91B
+62.5% YoY
|
2.28B
2.28B – 2.28B
+42.5% YoY
|
3.09B
2.60B – 3.69B
+35.6% YoY
|
3.76B
3.16B – 4.48B
+21.6% YoY
|
| EBITDA |
-175.40M
est: -5.06M (-3,368.2%)
|
-224.99M
est: -105.02M (-114.2%)
|
-272.60M
est: -138.73M (-96.5%)
|
-168.08M
est: -229.03M (+26.6%)
|
-354.46M
-404.27M – -313.17M
-54.8% YoY
|
-576.06M
-689.01M – -436.75M
-62.5% YoY
|
-820.67M
-820.67M – -820.67M
-42.5% YoY
|
-1.11B
-1.33B – -937.72M
-35.6% YoY
|
-1.35B
-1.62B – -1.14B
-21.6% YoY
|
| EBIT |
-179.80M
est: -5.49M (-3,176.0%)
|
-231.83M
est: -108.53M (-113.6%)
|
-280.56M
est: -143.36M (-95.7%)
|
-177.15M
est: -236.67M (+25.2%)
|
-366.28M
-417.75M – -323.61M
-54.8% YoY
|
-595.27M
-711.99M – -451.32M
-62.5% YoY
|
-848.04M
-848.04M – -848.04M
-42.5% YoY
|
-1.15B
-1.37B – -969.00M
-35.6% YoY
|
-1.40B
-1.67B – -1.18B
-21.6% YoY
|
| Net Income |
-187.13M
est: -207.59M (+9.9%)
|
-239.24M
est: -308.55M (+22.5%)
|
-287.22M
est: -246.90M (-16.3%)
|
-183.17M
est: -188.30M (+2.7%)
|
-98.44M
-301.94M – -3.19M
+47.7% YoY
|
326.97M
-494.40M – 734.82M
+432.1% YoY
|
826.05M
-204.21M – 1.61B
+152.6% YoY
|
1.22B
972.05M – 1.53B
+47.9% YoY
|
1.57B
1.25B – 1.96B
+28.2% YoY
|
| SGA |
159.25M
est: 69.94M (+127.7%)
|
323.12M
est: 427.73M (-24.5%)
|
411.36M
est: 565.03M (-27.2%)
|
570.60M
est: 932.79M (-38.8%)
|
1.44B
1.28B – 1.65B
+54.8% YoY
|
2.35B
1.78B – 2.81B
+62.5% YoY
|
3.34B
3.34B – 3.34B
+42.5% YoY
|
4.53B
3.82B – 5.41B
+35.6% YoY
|
5.51B
4.64B – 6.58B
+21.6% YoY
|
| EPS |
-4.60
est: -4.33 (-6.2%)
|
-5.27
est: -6.51 (+19.1%)
|
-5.99
est: -5.46 (-9.8%)
|
-3.68
est: -3.76 (+2.1%)
|
-1.96
-6.07 – -0.06
+47.8% YoY
|
5.78
-9.94 – 14.77
+394.6% YoY
|
14.40
-4.11 – 32.40
+149.2% YoY
|
24.56
19.54 – 30.76
+70.6% YoY
|
31.49
25.05 – 39.44
+28.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-05-04 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-01 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-63.00M
OE per share TTM
-1.25
Owner's Yield
-0.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
98
Total invested
433.23M
Insider transactions (90d)
6
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RTW Investments, LP | 2.98M | 6.90% | — | 2.98M | — | — | IA, PN | Delaware | 2023-02-14 | ↗ |
| 2 | Roderick Wong | 2.98M | 6.90% | — | 2.98M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 3 | Abigail P. Johnson | 2.87M | 15.00% | — | — | 2.87M | — | IN | Delaware | 2015-12-10 | ↗ |
| 4 | Edward C. Johnson 3d | 2.87M | 15.00% | — | — | 2.87M | — | IN | Delaware | 2015-12-10 | ↗ |
| 5 | FMR LLC | 2.87M | 15.00% | — | — | 2.87M | — | HC | Delaware | 2015-12-10 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 2.64M | 7.07% | — | 63.9K | — | 86.1K | IA | Pennsylvania | 2021-02-10 | ↗ |
| 7 | Fairmount Funds Management LLC | 2.34M | 5.00% | — | 2.34M | — | — | IA | Delaware | 2023-07-07 | ↗ |
| 8 | Peter Harwin | 2.34M | 5.00% | — | 2.34M | — | — | HC, IN | United States | 2023-07-07 | ↗ |
| 9 | Tomas Kiselak | 2.34M | 5.00% | — | 2.34M | — | — | HC, IN | Slovak Republic | 2023-07-07 | ↗ |
| 10 | Fairmount Healthcare Fund II L.P. | 2.28M | 4.90% | — | 2.28M | — | — | PN | Delaware | 2023-07-07 | ↗ |
| 11 | (1) BlackRock, Inc. | 2.11M | 5.60% | 2.08M | — | 2.11M | — | HC | Delaware | 2022-02-03 | ↗ |
| 12 | David L. Cohen | 2.06M | 5.50% | — | 2.06M | — | — | IN | Delaware | 2021-02-04 | ↗ |
| 13 | Harold J. Levy | 2.06M | 5.50% | — | 2.06M | — | — | IN | Delaware | 2021-02-04 | ↗ |
| 14 | Iridian Asset Management LLC | 2.06M | 5.50% | — | 2.06M | — | — | IA | Delaware | 2021-02-04 | ↗ |
| 15 | Select Biotechnology Portfolio | 1.91M | 10.00% | 1.91M | — | — | — | IV | Delaware | 2015-12-10 | ↗ |
| 16 | Koh, Bong | 1.64M | 5.00% | — | 1.64M | — | — | IN | Delaware | 2019-01-28 | ↗ |
| 17 | Shah, Nimish | 1.64M | 5.00% | — | 1.64M | — | — | IN | Delaware | 2019-01-28 | ↗ |
| 18 | VHCP Co-Investment Holdings II, LLC | 1.64M | 5.00% | — | 1.64M | — | — | OO | Delaware | 2019-01-28 | ↗ |
| 19 | VHCP Co-Investment Holdings III, LLC | 1.64M | 5.00% | — | 1.64M | — | — | OO | Delaware | 2019-01-28 | ↗ |
| 20 | VHCP Management II, LLC | 1.64M | 5.00% | — | 1.64M | — | — | OO | Delaware | 2019-01-28 | ↗ |
| 21 | VHCP Management III, LLC | 1.64M | 5.00% | — | 1.64M | — | — | OO | Delaware | 2019-01-28 | ↗ |
| 22 | Venrock Healthcare Capital Partners II, L.P. | 1.64M | 5.00% | — | 1.64M | — | — | PN | Delaware | 2019-01-28 | ↗ |
| 23 | Venrock Healthcare Capital Partners III, L.P. | 1.64M | 5.00% | — | 1.64M | — | — | PN | Delaware | 2019-01-28 | ↗ |
| 24 | JPMorgan Chase & Co. | 1.59M | 8.20% | 1.58M | — | — | — | HC | Delaware | 2017-01-13 | ↗ |
| 25 | Laurence W.Lytton | 1.30M | 5.50% | 1.27M | 31.4K | 1.27M | 31.4K | IN | USA | 2017-04-27 | ↗ |
| 26 | Fidelity Advisor Biotechnology Fund | 956.9K | 5.00% | 956.9K | — | — | — | IV | Delaware | 2015-12-10 | ↗ |
| 27 | Fairmount Healthcare Fund L.P. | 66.8K | 0.10% | — | 66.8K | — | — | PN | Delaware | 2023-07-07 | ↗ |
| 28 | PFM Health Sciences, LP | 6.00 | 5.40% | — | 2.16M | — | 2.16M | IA, PN, IN | Delaware | 2022-10-24 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
98
-322 vs prev Q
New positions
12
Closed positions
315
Increased
47
Reduced
27
Put/Call ratio
0.00
Calls held
600.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 989.4K +989.4K (+100.0%) | 180.71B +180.7B (+100.0%) | 1.98% +1.978 pp | 0.27% +0.273 pp | USD182.64 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 4.16M -15.8K (-0.4%) | 760.66M +252.9M (+49.8%) | 8.33% -0.130 pp | 0.01% +0.003 pp | USD58.73 +211.0% | 40 qtrs — |
| 3 | BLACKROCK, INC. | 3.91M +122.6K (+3.2%) | 714.77M +254.4M (+55.2%) | 7.82% +0.156 pp | 0.01% +0.004 pp | USD93.74 +94.8% | 6 qtrs — |
| 4 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.51M +472.4K (+45.5%) | 275.76M +149.8M (+118.9%) | 3.02% +0.920 pp | 0.03% +0.016 pp | USD133.15 +37.2% | 27 qtrs — |
| 5 | INVESCO LTD. | 1.27M +282.9K (+28.6%) | 232.59M +112.3M (+93.3%) | 2.55% +0.542 pp | 0.04% +0.017 pp | USD119.52 +52.8% | 28 qtrs — |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 1.22M -112.9K (-8.5%) | 223.12M +61.0M (+37.7%) | 2.44% -0.257 pp | 0.04% +0.011 pp | USD97.99 +86.4% | 11 qtrs — |
| 7 | FMR LLC | 1.18M +253.7K (+27.3%) | 215.81M +103.1M (+91.5%) | 2.36% +0.486 pp | 0.01% +0.005 pp | USD102.51 +78.2% | 26 qtrs — |
| 8 | DEEP TRACK CAPITAL, LP | 1.15M +250.0K (+27.8%) | 210.04M +100.7M (+92.2%) | 2.30% +0.479 pp | 3.74% +0.694 pp | USD122.86 +48.7% | 3 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.01M +12.5K (+1.3%) | 184.54M +63.4M (+52.3%) | 2.02% +0.002 pp | 0.01% +0.004 pp | USD56.92 +220.9% | 40 qtrs — |
| 10 | STATE STREET CORP | 958.2K +15.2K (+1.6%) | 175.00M +60.5M (+52.8%) | 1.92% +0.008 pp | 0.01% +0.002 pp | USD49.82 +266.6% | 28 qtrs — |
| 11 | RTW INVESTMENTS, LP | 888.0K -230.9K (-20.6%) | 162.18M +26.3M (+19.4%) | 1.78% -0.488 pp | 1.62% -0.050 pp | USD62.79 +190.9% | 28 qtrs — |
| 12 | ALETHEA CAPITAL MANAGEMENT, LLC | 668.7K -2.2K (-0.3%) | 122.13M +40.7M (+49.9%) | 1.34% -0.020 pp | 59.30% +6.958 pp | USD12.65 +1,343.8% | 33 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 618.0K +256.8K (+71.1%) | 112.88M +69.0M (+157.3%) | 1.24% +0.505 pp | 0.01% +0.005 pp | USD136.09 +34.2% | 29 qtrs — |
| 14 | EVENTIDE ASSET MANAGEMENT, LLC | 571.2K -175.2K (-23.5%) | 104.20M +13.6M (+15.0%) | 1.14% -0.368 pp | 1.63% +0.137 pp | USD78.16 +133.7% | 10 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 549.1K +252.8K (+85.3%) | 100.29M +64.3M (+178.7%) | 1.10% +0.499 pp | 0.06% +0.035 pp | USD147.42 +23.9% | 9 qtrs — |
| 16 | NORGES BANK | 495.5K +495.5K (+100.0%) | 90.49M +90.5M (+100.0%) | 0.99% +0.991 pp | 0.01% +0.010 pp | USD182.64 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 491.2K +81.6K (+19.9%) | 89.71M +40.0M (+80.4%) | 0.98% +0.154 pp | 0.01% +0.002 pp | USD93.90 +94.5% | 41 qtrs — |
| 18 | ASSENAGON ASSET MANAGEMENT S.A. | 468.0K +173.2K (+58.8%) | 85.47M +49.7M (+138.7%) | 0.94% +0.339 pp | 0.12% +0.069 pp | USD142.15 +28.5% | 7 qtrs — |
| 19 | PICTET ASSET MANAGEMENT HOLDING SA | 436.1K +73.9K (+20.4%) | 79.64M +35.7M (+81.1%) | 0.87% +0.139 pp | 0.08% +0.035 pp | USD125.47 +45.6% | 10 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 402.7K +20.7K (+5.4%) | 73.55M +27.1M (+58.5%) | 0.81% +0.032 pp | 0.01% +0.004 pp | USD63.66 +186.9% | 27 qtrs — |
| 21 | NORTHERN TRUST CORP | 390.4K -19.1K (-4.7%) | 71.31M +21.6M (+43.4%) | 0.78% -0.048 pp | 0.01% +0.003 pp | USD45.98 +297.2% | 39 qtrs — |
| 22 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 367.6K -77.4K (-17.4%) | 67.13M +13.1M (+24.2%) | 0.73% -0.165 pp | 0.10% +0.016 pp | USD101.35 +80.2% | 16 qtrs — |
| 23 | HOOD RIVER CAPITAL MANAGEMENT LLC | 366.2K +6.2K (+1.7%) | 66.88M +23.2M (+53.0%) | 0.73% +0.004 pp | 0.73% +0.217 pp | USD105.72 +72.8% | 13 qtrs — |
| 24 | PRINCIPAL FINANCIAL GROUP INC | 363.1K -5.3K (-1.4%) | 66.32M +21.6M (+48.2%) | 0.73% -0.019 pp | 0.03% +0.011 pp | USD96.65 +89.0% | 25 qtrs — |
| 25 | UBS GROUP AG | 355.3K +142.9K (+67.2%) | 64.90M +39.1M (+151.5%) | 0.71% +0.281 pp | 0.01% +0.007 pp | USD134.02 +36.3% | 28 qtrs — |
| 26 | NUVEEN, LLC | 349.2K +50.9K (+17.1%) | 63.78M +27.5M (+76.0%) | 0.70% +0.095 pp | 0.02% +0.007 pp | USD126.46 +44.4% | 4 qtrs — |
| 27 | FRANKLIN RESOURCES INC | 342.6K +57.0K (+19.9%) | 62.57M +27.9M (+80.4%) | 0.68% +0.107 pp | 0.02% +0.007 pp | USD107.16 +70.4% | 13 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 325.4K -186.0 (-0.1%) | 59.44M +19.9M (+50.3%) | 0.65% -0.008 pp | 0.06% +0.020 pp | USD100.88 +81.0% | 8 qtrs — |
| 29 | MARSHALL WACE, LLP | 320.6K -57.5K (-15.2%) | 58.55M +12.6M (+27.5%) | 0.64% -0.124 pp | 0.05% +0.007 pp | USD115.92 +57.6% | 5 qtrs — |
| 30 | LOOMIS SAYLES & CO L P | 315.4K -14.7K (-4.5%) | 57.60M +17.5M (+43.7%) | 0.63% -0.037 pp | 0.07% +0.022 pp | USD85.15 +114.5% | 8 qtrs — |
| 31 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 311.9K +26.9K (+9.4%) | 56.97M +22.4M (+64.6%) | 0.62% +0.047 pp | 0.01% +0.003 pp | USD84.28 +116.7% | 33 qtrs — |
| 32 | BNP PARIBAS ARBITRAGE, SNC | 304.4K +114.3K (+60.1%) | 55.59M +32.5M (+140.8%) | 0.61% +0.224 pp | 0.03% +0.013 pp | USD121.90 +49.8% | 39 qtrs — |
| 33 | GOLDMAN SACHS GROUP INC | 300.9K +76.8K (+34.2%) | 54.96M +27.7M (+101.9%) | 0.60% +0.148 pp | 0.01% +0.003 pp | USD106.38 +71.7% | 28 qtrs — |
| 34 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 278.8K -47.5K (-14.6%) | 50.93M +11.3M (+28.5%) | 0.56% -0.103 pp | 4.52% +1.457 pp | USD111.79 +63.4% | 5 qtrs — |
| 35 | BANK OF NEW YORK MELLON CORP | 255.1K +1.8K (+0.7%) | 46.59M +15.8M (+51.5%) | 0.51% -0.002 pp | 0.01% +0.002 pp | USD75.46 +142.0% | 29 qtrs — |
| 36 | ORBIMED ADVISORS LLC | 253.1K -278.7K (-52.4%) | 46.23M -18.4M (-28.4%) | 0.51% -0.570 pp | 0.95% -0.575 pp | USD116.62 +56.6% | 4 qtrs — |
| 37 | PFM HEALTH SCIENCES, LP | 251.6K -278.8K (-52.6%) | 45.95M -18.5M (-28.7%) | 0.50% -0.570 pp | 4.58% -0.372 pp | USD59.23 +208.4% | 15 qtrs — |
| 38 | JPMORGAN CHASE & CO | 233.2K -17.3K (-6.9%) | 42.59M +12.2M (+40.0%) | 0.47% -0.041 pp | 0.00% +0.001 pp | USD82.48 +121.4% | 27 qtrs — |
| 39 | MAN GROUP PLC | 228.6K -59.3K (-20.6%) | 41.76M +6.8M (+19.4%) | 0.46% -0.125 pp | 0.07% +0.010 pp | USD106.39 +71.7% | 5 qtrs — |
| 40 | DRIEHAUS CAPITAL MANAGEMENT LLC | 220.5K -2.9K (-1.3%) | 40.28M +13.1M (+48.4%) | 0.44% -0.011 pp | 0.27% +0.079 pp | USD116.13 +57.3% | 4 qtrs — |
| 41 | VESTAL POINT CAPITAL, LP | 210.0K +60.0K (+40.0%) | 38.35M +20.1M (+110.5%) | 0.42% +0.116 pp | 1.30% +0.481 pp | USD138.93 +31.5% | 2 qtrs — |
| 42 | FIRST TURN MANAGEMENT, LLC | 206.9K +54.3K (+35.6%) | 37.79M +19.3M (+103.9%) | 0.41% +0.105 pp | 4.32% +1.535 pp | USD111.24 +64.2% | 9 qtrs — |
| 43 | CITIGROUP INC | 204.1K +62.1K (+43.7%) | 37.28M +20.0M (+116.1%) | 0.41% +0.121 pp | 0.02% +0.009 pp | USD127.55 +43.2% | 28 qtrs — |
| 44 | TRI LOCUM PARTNERS LP | 201.6K -90.5K (-31.0%) | 36.83M +1.3M (+3.8%) | 0.40% -0.188 pp | 4.78% -3.374 pp | USD104.70 +74.4% | 13 qtrs — |
| 45 | TWO SIGMA ADVISERS, LP | 188.5K +188.5K (+100.0%) | 34.43M +34.4M (+100.0%) | 0.38% +0.377 pp | 0.07% +0.067 pp | USD182.64 +0.0% | 1 qtrs NEW |
| 46 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 188.3K -20.8K (-10.0%) | 34.38M +9.0M (+35.4%) | 0.38% -0.047 pp | 0.09% +0.010 pp | USD103.50 +76.5% | 5 qtrs — |
| 47 | CITADEL ADVISORS LLC | 176.0K +85.3K (+94.0%) | 32.14M +21.1M (+191.8%) | 0.35% +0.168 pp | 0.00% +0.003 pp | USD128.29 +42.4% | 28 qtrs — |
| 48 | VOYA INVESTMENT MANAGEMENT LLC | 173.3K +59.3K (+52.0%) | 31.65M +17.8M (+128.5%) | 0.35% +0.116 pp | 0.03% +0.017 pp | USD119.81 +52.4% | 27 qtrs — |
| 49 | RENAISSANCE TECHNOLOGIES LLC | 170.0K +20.0K (+13.3%) | 31.05M +12.8M (+70.4%) | 0.34% +0.037 pp | 0.05% +0.024 pp | USD124.41 +46.8% | 4 qtrs — |
| 50 | METLIFE INVESTMENT MANAGEMENT, LLC | 164.9K -32.4K (-16.4%) | 30.11M +6.1M (+25.7%) | 0.33% -0.070 pp | 0.15% +0.031 pp | USD108.77 +67.9% | 27 qtrs — |
| 51 | FRONTIER CAPITAL MANAGEMENT CO LLC | 157.7K +31.3K (+24.8%) | 28.80M +13.5M (+87.6%) | 0.32% +0.060 pp | 0.31% +0.168 pp | USD125.40 +45.6% | 13 qtrs — |
| 52 | SQUAREPOINT OPS LLC | 155.0K +— (+0.0%) | 28.31M +9.5M (+50.4%) | 0.31% -0.004 pp | 0.03% +0.011 pp | USD97.46 +87.4% | 5 qtrs — |
| 53 | WOODLINE PARTNERS LP | 150.9K -181.0K (-54.5%) | 27.55M -12.8M (-31.6%) | 0.30% -0.370 pp | 0.11% -0.083 pp | USD76.59 +138.5% | 13 qtrs — |
| 54 | ALGERT GLOBAL LLC | 149.4K +105.2K (+238.4%) | 27.29M +21.9M (+408.9%) | 0.30% +0.209 pp | 0.43% +0.336 pp | USD162.41 +12.5% | 4 qtrs — |
| 55 | PERCEPTIVE ADVISORS LLC | 148.9K +— (+0.0%) | 27.20M +9.1M (+50.4%) | 0.30% -0.004 pp | 0.48% -0.038 pp | USD81.55 +124.0% | 11 qtrs — |
| 56 | TWO SIGMA INVESTMENTS, LP | 145.6K +137.4K (+1,674.1%) | 26.59M +25.6M (+2,567.9%) | 0.29% +0.275 pp | 0.04% +0.036 pp | USD179.19 +1.9% | 4 qtrs — |
| 57 | RAYMOND JAMES FINANCIAL INC | 150.1K -8.6K (-5.4%) | 24.78M +5.5M (+28.6%) | 0.30% -0.021 pp | 0.01% +0.002 pp | USD85.39 +113.9% | 5 qtrs — |
| 58 | US BANCORP \DE\ | 131.0K -548.0 (-0.4%) | 23.92M +7.9M (+49.8%) | 0.26% -0.004 pp | 0.03% +0.009 pp | USD41.63 +338.7% | 27 qtrs — |
| 59 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 133.9K +1.2K (+0.9%) | 23.66M +7.5M (+46.8%) | 0.27% -0.001 pp | 0.02% +0.006 pp | USD97.68 +87.0% | 27 qtrs — |
| 60 | CAPTION MANAGEMENT, LLC | 125.0K +100.0K (+400.0%) | 22.83M +19.8M (+651.9%) | 0.25% +0.199 pp | 0.16% +0.133 pp | USD163.32 +11.8% | 17 qtrs — |
| 61 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 114.8K -58.0K (-33.6%) | 20.97M -19.5K (-0.1%) | 0.23% -0.120 pp | 1.96% -0.363 pp | USD97.15 +88.0% | 12 qtrs — |
| 62 | VOLEON CAPITAL MANAGEMENT LP | 110.2K +93.4K (+558.4%) | 20.12M +18.1M (+890.1%) | 0.22% +0.186 pp | 0.43% +0.383 pp | USD173.35 +5.4% | 2 qtrs — |
| 63 | EMERALD ADVISERS, LLC | 108.1K -860.0 (-0.8%) | 19.74M +6.5M (+49.2%) | 0.22% -0.004 pp | 0.61% +0.184 pp | USD104.39 +75.0% | 3 qtrs — |
| 64 | AQR CAPITAL MANAGEMENT LLC | 103.4K -15.2K (-12.8%) | 18.89M +4.5M (+31.1%) | 0.21% -0.033 pp | 0.01% +0.001 pp | USD99.41 +83.7% | 15 qtrs — |
| 65 | CANADA PENSION PLAN INVESTMENT BOARD | 103.2K +38.8K (+60.2%) | 18.85M +11.0M (+141.0%) | 0.21% +0.076 pp | 0.01% +0.007 pp | USD137.38 +32.9% | 5 qtrs — |
| 66 | DNB ASSET MANAGEMENT AS | 101.1K -879.0 (-0.9%) | 18.47M +6.1M (+49.1%) | 0.20% -0.004 pp | 0.06% +0.018 pp | USD96.37 +89.5% | 8 qtrs — |
| 67 | AMERIPRISE FINANCIAL INC | 99.9K -8.3K (-7.7%) | 18.25M +5.1M (+38.8%) | 0.20% -0.019 pp | 0.00% +0.001 pp | USD107.87 +69.3% | 14 qtrs — |
| 68 | DEUTSCHE BANK AG\ | 98.3K +1.6K (+1.6%) | 17.95M +6.2M (+52.8%) | 0.20% +0.001 pp | 0.01% +0.002 pp | USD76.39 +139.1% | 27 qtrs — |
| 69 | ABRDN PLC | 97.4K +2.8K (+2.9%) | 17.79M +6.3M (+54.8%) | 0.19% +0.003 pp | 0.03% +0.009 pp | USD95.49 +91.3% | 7 qtrs — |
| 70 | ROYCE & ASSOCIATES LP | 94.0K +38.0K (+67.8%) | 17.17M +10.4M (+152.3%) | 0.19% +0.075 pp | 0.17% +0.106 pp | USD135.71 +34.6% | 8 qtrs — |
| 71 | NICHOLAS INVESTMENT PARTNERS, LP | 91.6K +42.9K (+88.2%) | 16.72M +10.8M (+183.0%) | 0.18% +0.085 pp | 1.22% +0.766 pp | USD145.04 +25.9% | 13 qtrs — |
| 72 | WCM INVESTMENT MANAGEMENT, LLC | 112.1K -7.6K (-6.4%) | 16.67M +2.6M (+18.4%) | 0.22% -0.018 pp | 0.03% +0.005 pp | USD62.12 +194.0% | 24 qtrs — |
| 73 | M&G PLC | 90.3K +90.3K (+100.0%) | 16.53M +16.5M (+100.0%) | 0.18% +0.181 pp | 0.08% +0.085 pp | USD182.64 +0.0% | 1 qtrs NEW |
| 74 | WELLS FARGO & COMPANY/MN | 89.7K +34.4K (+62.2%) | 16.38M +9.7M (+143.9%) | 0.18% +0.067 pp | 0.00% +0.002 pp | USD122.09 +49.6% | 40 qtrs — |
| 75 | FEDERATED HERMES, INC. | 87.3K +30.0K (+52.4%) | 15.94M +9.0M (+129.1%) | 0.17% +0.059 pp | 0.03% +0.014 pp | USD135.09 +35.2% | 4 qtrs — |
| 76 | UBS ASSET MANAGEMENT AMERICAS INC | 87.2K +558.0 (+0.6%) | 15.94M +5.4M (+51.4%) | 0.17% -0.001 pp | 0.00% +0.001 pp | USD94.12 +94.1% | 27 qtrs — |
| 77 | GRANITE INVESTMENT PARTNERS, LLC | 84.9K -3.7K (-4.1%) | 15.51M +4.7M (+44.2%) | 0.17% -0.009 pp | 0.92% +0.308 pp | USD95.47 +91.3% | 5 qtrs — |
| 78 | SPEARS ABACUS ADVISORS LLC | 84.2K +3.0 (+0.0%) | 15.37M +5.1M (+50.4%) | 0.17% -0.002 pp | 0.29% +0.095 pp | USD78.02 +134.1% | 8 qtrs — |
| 79 | BARCLAYS PLC | 76.9K +15.1K (+24.4%) | 14.04M +8.5M (+152.8%) | 0.15% +0.029 pp | 0.00% +0.002 pp | USD111.88 +63.2% | 11 qtrs — |
| 80 | CORMORANT ASSET MANAGEMENT, LP | 75.0K -25.0K (-25.0%) | 13.70M +1.6M (+12.8%) | 0.15% -0.052 pp | 0.63% -0.205 pp | USD81.03 +125.4% | 7 qtrs — |
| 81 | IRIDIAN ASSET MANAGEMENT LLC/CT | 73.8K -9.8K (-11.7%) | 13.48M +3.3M (+32.8%) | 0.15% -0.022 pp | 4.96% +0.968 pp | USD71.81 +154.3% | 28 qtrs — |
| 82 | SUMMIT FINANCIAL, LLC | 70.6K -6.9K (-8.9%) | 12.90M +3.5M (+37.0%) | 0.14% -0.016 pp | 0.19% +0.046 pp | USD121.45 +50.4% | 2 qtrs — |
| 83 | NEUBERGER BERMAN GROUP LLC | 69.5K -21.7K (-23.8%) | 12.69M +1.6M (+14.6%) | 0.14% -0.046 pp | 0.01% +0.001 pp | USD108.23 +68.8% | 3 qtrs — |
| 84 | SWISS NATIONAL BANK | 68.9K +2.1K (+3.1%) | 12.58M +4.5M (+55.1%) | 0.14% +0.003 pp | 0.01% +0.003 pp | USD57.14 +219.6% | 27 qtrs — |
| 85 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 68.9K +956.0 (+1.4%) | 12.58M +4.3M (+52.5%) | 0.14% +0.000 pp | 0.02% +0.007 pp | USD118.33 +54.3% | 4 qtrs — |
| 86 | EMERALD MUTUAL FUND ADVISERS TRUST | 67.6K +2.1K (+3.2%) | 12.35M +4.4M (+55.2%) | 0.14% +0.003 pp | 0.60% +0.191 pp | USD107.22 +70.3% | 3 qtrs — |
| 87 | AXIOM INVESTORS LLC /DE | 63.4K +14.1K (+28.7%) | 11.58M +5.6M (+93.5%) | 0.13% +0.027 pp | 0.10% +0.058 pp | USD132.88 +37.4% | 4 qtrs — |
| 88 | IFP ADVISORS, INC | 62.4K -865.0 (-1.4%) | 11.41M +3.7M (+48.3%) | 0.12% -0.003 pp | 0.26% +0.056 pp | USD88.59 +106.2% | 6 qtrs — |
| 89 | WALLEYE CAPITAL LLC | 60.1K +59.6K (+11,920.0%) | 10.98M +10.9M (+17,976.0%) | 0.12% +0.119 pp | 0.03% +0.033 pp | USD181.83 +0.4% | 8 qtrs — |
| 90 | PRIVIUM FUND MANAGEMENT B.V. | 56.9K +4.1K (+7.9%) | 10.39M +4.0M (+62.2%) | 0.11% +0.007 pp | 1.91% +0.761 pp | USD74.02 +146.7% | 12 qtrs — |
| 91 | EDGESTREAM PARTNERS, L.P. | 56.4K +38.0K (+207.2%) | 10.29M +8.1M (+362.0%) | 0.11% +0.076 pp | 0.29% +0.225 pp | USD161.15 +13.3% | 4 qtrs — |
| 92 | HIGHTOWER ADVISORS, LLC | 56.0K -1.1K (-2.0%) | 10.22M +3.3M (+47.4%) | 0.11% -0.004 pp | 0.01% +0.003 pp | USD114.42 +59.6% | 5 qtrs — |
| 93 | ATIKA CAPITAL MANAGEMENT LLC | 55.5K +6.5K (+13.3%) | 10.14M +4.2M (+70.3%) | 0.11% +0.012 pp | 1.07% +0.588 pp | USD107.71 +69.6% | 15 qtrs — |
| 94 | JANE STREET GROUP, LLC | 54.8K +1.5K (+2.8%) | 10.01M +3.5M (+54.6%) | 0.11% +0.002 pp | 0.00% +0.001 pp | USD110.49 +65.3% | 6 qtrs — |
| 95 | ALLIANCEBERNSTEIN L.P. | 53.1K -9.9K (-15.7%) | 9.71M +2.0M (+26.7%) | 0.11% -0.021 pp | 0.00% +0.001 pp | USD94.01 +94.3% | 27 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Ratio by volume
3.00
Bullish
Buys
6
Sells
2
Shares acquired
62.9K
Shares disposed
15.0K
Cash buys
—
Cash sales
1.00
Net activity
+47,886
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Maizel Ari | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 70.73 | 530.5K | 23,710 | D | ↗ |
| 2026-04-21 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Performance Stock Units | 24,081 | 0.00 | — | 24,081 | D | ↗ |
| 2026-04-21 | Pizzie Nick | Officer | A-Award | A | Performance Stock Units | 8,188 | 0.00 | — | 8,188 | D | ↗ |
| 2026-04-21 | Murdock Hunter R. | Officer | A-Award | A | Performance Stock Units | 7,224 | 0.00 | — | 7,224 | D | ↗ |
| 2026-04-21 | Maizel Ari | Officer | A-Award | A | Performance Stock Units | 7,224 | 0.00 | — | 7,224 | D | ↗ |
| 2026-04-21 | Jacobson Mark L. | Officer | A-Award | A | Performance Stock Units | 8,669 | 0.00 | — | 8,669 | D | ↗ |
| 2026-02-26 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 54,623 | 0.00 | — | 54,623 | D | ↗ |
| 2026-02-26 | Pizzie Nick | Officer | A-Award | A | Restricted Stock Units | 18,570 | 0.00 | — | 18,570 | D | ↗ |
| 2026-02-26 | Murdock Hunter R. | Officer | A-Award | A | Restricted Stock Units | 16,385 | 0.00 | — | 16,385 | D | ↗ |
| 2026-02-26 | Maizel Ari | Officer | A-Award | A | Restricted Stock Units | 16,385 | 0.00 | — | 16,385 | D | ↗ |
| 2026-02-26 | Jacobson Mark L. | Officer | A-Award | A | Restricted Stock Units | 19,663 | 0.00 | — | 19,663 | D | ↗ |
| 2026-02-26 | Coleman Mark | Director | S-Sale | D | Common Stock | 25,000 | 161.11 | 4.03M | 47,140 | D | ↗ |
| 2026-02-23 | Coleman Mark | Director | M-Exempt | A | Common Stock | 6,250 | 4.95 | 30.9K | 72,140 | D | ↗ |
| 2026-02-20 | Coleman Mark | Director | M-Exempt | A | Common Stock | 12,485 | 4.95 | 61.8K | 65,890 | D | ↗ |
| 2026-02-10 | Coleman Mark | Director | M-Exempt | A | Common Stock | 5,193 | 8.02 | 41.6K | 53,405 | D | ↗ |
| 2026-02-02 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 32,410 | 185.60 | 6.02M | 7,229 | D | ↗ |
| 2026-01-22 | Pizzie Nick | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 3.50 | 42.0K | 105,000 | D | ↗ |
| 2026-01-21 | Maizel Ari | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 70.73 | 530.5K | 31,210 | D | ↗ |
| 2026-01-07 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 31,261 | 8.02 | 250.7K | 38,490 | D | ↗ |
| 2026-01-06 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 29,450 | 172.33 | 5.08M | 7,229 | D | ↗ |
| 2026-01-05 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 78,703 | 8.02 | 631.2K | 85,932 | D | ↗ |
| 2025-12-31 | Saad Mark E | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,231 | 8.02 | 50.0K | 0 | D | ↗ |
| 2025-12-04 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 10,558 | 8.02 | 84.7K | 17,787 | D | ↗ |
| 2025-12-03 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 20,163 | 8.02 | 161.7K | 27,392 | D | ↗ |
| 2025-12-02 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 49,252 | 8.02 | 395.0K | 56,481 | D | ↗ |
| 2025-11-05 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 21,775 | 134.49 | 2.93M | 251,797 | D | ↗ |
| 2025-11-04 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 50,459 | 133.79 | 6.75M | 273,572 | D | ↗ |
| 2025-11-03 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 91,705 | 132.34 | 12.14M | 324,031 | D | ↗ |
| 2025-10-08 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 12,774 | 8.02 | 102.4K | 20,003 | D | ↗ |
| 2025-10-07 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 13,390 | 8.02 | 107.4K | 20,619 | D | ↗ |
| 2025-10-06 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 19,220 | 8.02 | 154.1K | 26,449 | D | ↗ |
| 2025-09-22 | Jacobson Mark L. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 35,378 | D | ↗ |
| 2025-09-16 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 19,719 | 114.19 | 2.25M | 7,229 | D | ↗ |
| 2025-09-16 | Jacobson Mark L. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 4.95 | 123.8K | 0 | D | ↗ |
| 2025-09-15 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 15,254 | 117.37 | 1.79M | 480,839 | D | ↗ |
| 2025-09-12 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 27,907 | 118.96 | 3.32M | 496,093 | D | ↗ |
| 2025-09-08 | Coleman Mark | Director | P-Purchase | A | Common Stock | 488 | 127.40 | 62.2K | 48,212 | D | ↗ |
| 2025-09-05 | Saad Mark E | Director | S-Sale | D | Common Stock | 9,127 | 125.07 | 1.14M | 10,002 | D | ↗ |
| 2025-09-02 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 13,464 | 123.68 | 1.67M | 57,510 | D | ↗ |
| 2025-08-29 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 20,000 | 121.27 | 2.43M | 70,974 | D | ↗ |
| 2025-08-28 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 20,000 | 121.60 | 2.43M | 90,974 | D | ↗ |
| 2025-08-27 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 20,000 | 122.30 | 2.45M | 110,974 | D | ↗ |
| 2025-08-26 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 20,000 | 120.03 | 2.40M | 130,974 | D | ↗ |
| 2025-08-22 | JEFFS ROGER | Director | S-Sale | D | Common Stock | 16,694 | 120.08 | 2.00M | 150,974 | D | ↗ |
| 2025-06-23 | Murdock Hunter R. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,014 | 29.91 | 179.9K | 16,369 | D | ↗ |
| 2025-06-20 | Murdock Hunter R. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 29.91 | 224.3K | 22,383 | D | ↗ |
| 2025-06-18 | Murdock Hunter R. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 29.91 | 224.3K | 29,883 | D | ↗ |
| 2025-06-17 | Murdock Hunter R. | Officer | S-Sale | D | Common Stock | 7,500 | 100.26 | 752.0K | 0 | D | ↗ |
| 2025-06-16 | Murdock Hunter R. | Officer | S-Sale | D | Common Stock | 7,500 | 102.42 | 768.2K | 0 | D | ↗ |
| 2025-06-09 | Jacobson Mark L. | Officer | M-Exempt | A | Common Stock | 25,000 | 8.02 | 200.5K | 30,783 | D | ↗ |
| 2025-06-06 | Saad Mark E | Director | A-Award | A | Restricted Stock Units | 1,429 | 0.00 | — | 1,429 | D | ↗ |
| 2025-06-06 | Mahony Susan | Director | A-Award | A | Restricted Stock Units | 1,429 | 0.00 | — | 1,429 | D | ↗ |
| 2025-06-06 | JEFFS ROGER | Director | A-Award | A | Restricted Stock Units | 1,429 | 0.00 | — | 1,429 | D | ↗ |
| 2025-06-06 | Coleman Mark | Director | A-Award | A | Restricted Stock Units | 1,429 | 0.00 | — | 1,429 | D | ↗ |
| 2025-05-28 | Jacobson Mark L. | Officer | M-Exempt | A | Common Stock | 20,000 | 6.47 | 129.4K | 25,783 | D | ↗ |
| 2025-05-28 | Coleman Mark | Director | S-Sale | D | Common Stock | 3,750 | 103.43 | 387.9K | 46,637 | D | ↗ |
| 2025-05-27 | Jacobson Mark L. | Officer | S-Sale | D | Common Stock | 20,673 | 104.66 | 2.16M | 5,783 | D | ↗ |
| 2025-05-27 | Coleman Mark | Director | S-Sale | D | Common Stock | 3,750 | 105.47 | 395.5K | 50,387 | D | ↗ |
| 2025-05-20 | Coleman Mark | Director | S-Sale | D | Common Stock | 3,000 | 107.49 | 322.5K | 54,137 | D | ↗ |
| 2025-02-24 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Performance Stock Units | 28,609 | 0.00 | — | 28,609 | D | ↗ |
| 2025-02-24 | Pizzie Nick | Officer | A-Award | A | Performance Stock Units | 9,423 | 0.00 | — | 9,423 | D | ↗ |
| 2025-02-24 | Murdock Hunter R. | Officer | A-Award | A | Performance Stock Units | 7,740 | 0.00 | — | 7,740 | D | ↗ |
| 2025-02-24 | Maizel Ari | Officer | A-Award | A | Performance Stock Units | 7,740 | 0.00 | — | 7,740 | D | ↗ |
| 2025-02-24 | Jacobson Mark L. | Officer | A-Award | A | Performance Stock Units | 10,769 | 0.00 | — | 10,769 | D | ↗ |
| 2025-02-21 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 28,609 | 0.00 | — | 28,609 | D | ↗ |
| 2025-02-21 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 1,494 | 137.75 | 205.8K | 1,494 | D | ↗ |
| 2025-02-21 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 9,516 | 137.75 | 1.31M | 9,516 | D | ↗ |
| 2025-02-21 | Murdock Hunter R. | Officer | A-Award | A | Restricted Stock Units | 7,740 | 0.00 | — | 7,740 | D | ↗ |
| 2025-02-21 | Maizel Ari | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 7,816 | 137.75 | 1.08M | 7,816 | D | ↗ |
| 2025-02-21 | Mahony Susan | Director | A-Award | A | Stock Option (Right to Buy) | 1,312 | 137.75 | 180.7K | 1,312 | D | ↗ |
| 2025-02-21 | Jacobson Mark L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 10,875 | 137.75 | 1.50M | 10,875 | D | ↗ |
| 2025-02-21 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 1,408 | 137.75 | 194.0K | 1,408 | D | ↗ |
| 2025-02-14 | Pizzie Nick | Officer | M-Exempt | A | Common Stock | 3,000 | 3.50 | 10.5K | 45,187 | D | ↗ |
| 2025-02-13 | Pizzie Nick | Officer | M-Exempt | A | Common Stock | 12,000 | 3.50 | 42.0K | 54,187 | D | ↗ |
| 2025-01-03 | Coleman Mark | Director | M-Exempt | D | Stock Option (Right to Buy) | 9,127 | 9.00 | 82.1K | 0 | D | ↗ |
| 2024-11-19 | Coleman Mark | Director | M-Exempt | A | Common Stock | 33,410 | 5.94 | 198.5K | 48,010 | D | ↗ |
| 2024-10-14 | Maizel Ari | Officer | — | — | Stock Option (Right to Buy) | 38,710 | 70.73 | 2.74M | 0 | D | ↗ |
| 2024-09-11 | Saad Mark E | Director | M-Exempt | A | Common Stock | 11,016 | 3.67 | 40.4K | 21,018 | — | ↗ |
| 2024-08-09 | Jacobson Mark L. | Officer | M-Exempt | A | Common Stock | 47,739 | 4.04 | 192.9K | 53,522 | — | ↗ |
| 2024-06-07 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 5,799 | 73.90 | 428.5K | 5,799 | — | ↗ |
| 2024-06-07 | Mahony Susan | Director | A-Award | A | Stock Option (Right to Buy) | 5,799 | 73.90 | 428.5K | 5,799 | — | ↗ |
| 2024-06-07 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 5,799 | 73.90 | 428.5K | 5,799 | — | ↗ |
| 2024-06-07 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 5,799 | 73.90 | 428.5K | 5,799 | — | ↗ |
| 2024-05-29 | Jacobson Mark L. | Officer | M-Exempt | A | Common Stock | 13,693 | 1.30 | 17.8K | 13,693 | — | ↗ |
| 2024-05-29 | Coleman Mark | Director | S-Sale | D | Common Stock | 5,248 | 75.14 | 394.3K | 14,600 | — | ↗ |
| 2024-05-28 | Coleman Mark | Director | S-Sale | D | Common Stock | 5,249 | 75.21 | 394.8K | 19,848 | — | ↗ |
| 2024-04-01 | Jacobson Mark L. | Officer | M-Exempt | A | Common Stock | 24,662 | 1.30 | 32.1K | 24,662 | — | ↗ |
| 2024-03-15 | JEFFS ROGER | Director | M-Exempt | A | Common Stock | 2,347 | 29.91 | 70.2K | 123,103 | — | ↗ |
| 2024-03-14 | JEFFS ROGER | Director | M-Exempt | A | Common Stock | 13,000 | 22.03 | 286.4K | 133,756 | — | ↗ |
| 2024-02-27 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 47,886 | 0.00 | — | 47,886 | — | ↗ |
| 2024-02-27 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 1,519 | 84.00 | 127.6K | 1,519 | — | ↗ |
| 2024-02-27 | Pizzie Nick | Officer | A-Award | A | Restricted Stock Units | 15,774 | 0.00 | — | 15,774 | — | ↗ |
| 2024-02-27 | Murdock Hunter R. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 23,593 | 84.00 | 1.98M | 23,593 | — | ↗ |
| 2024-02-27 | Mahony Susan | Director | A-Award | A | Stock Option (Right to Buy) | 191 | 84.00 | 16.0K | 191 | — | ↗ |
| 2024-02-27 | Jacobson Mark L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 32,825 | 84.00 | 2.76M | 32,825 | — | ↗ |
| 2024-02-27 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 1,425 | 84.00 | 119.7K | 1,425 | — | ↗ |
| 2023-10-10 | Mahony Susan | Director | A-Award | A | Stock Option (Right to Buy) | 5,873 | 70.56 | 414.4K | 5,873 | — | ↗ |
| 2023-09-15 | Coleman Mark | Director | S-Sale | D | Common Stock | 18,572 | 75.18 | 1.40M | 403,856 | — | ↗ |
| 2023-06-02 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 5,681 | 74.12 | 421.1K | 5,681 | — | ↗ |
| 2023-06-02 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 5,681 | 74.12 | 421.1K | 5,681 | — | ↗ |
| 2023-06-02 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 5,681 | 74.12 | 421.1K | 5,681 | — | ↗ |
| 2023-03-02 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 62,400 | 0.00 | — | 62,400 | — | ↗ |
| 2023-03-02 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 2,224 | 65.32 | 145.3K | 2,224 | — | ↗ |
| 2023-03-02 | Pizzie Nick | Officer | A-Award | A | Restricted Stock Units | 20,554 | 0.00 | — | 20,554 | — | ↗ |
| 2023-03-02 | Murdock Hunter R. | Officer | A-Award | A | Restricted Stock Units | 16,883 | 0.00 | — | 16,883 | — | ↗ |
| 2023-03-02 | Jacobson Mark L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 41,424 | 65.32 | 2.71M | 41,424 | — | ↗ |
| 2023-03-02 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 2,082 | 65.32 | 136.0K | 2,082 | — | ↗ |
| 2023-03-02 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 2,870 | 65.32 | 187.5K | 2,870 | — | ↗ |
| 2023-01-03 | Coleman Mark | Director | M-Exempt | A | Common Stock | 17,501 | 1.30 | 22.8K | 25,097 | — | ↗ |
| 2022-06-13 | Murdock Hunter R. | Officer | — | D | Stock Option (Right to Buy) | 52,383 | 29.91 | 1.57M | 0 | — | ↗ |
| 2022-06-03 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 16,976 | 25.53 | 433.4K | 16,976 | — | ↗ |
| 2022-06-03 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 16,976 | 0.00 | — | 16,976 | — | ↗ |
| 2022-06-03 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 16,976 | 0.00 | — | 16,976 | — | ↗ |
| 2022-03-15 | Coleman Mark | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,496 | 0.00 | — | 17,501 | — | ↗ |
| 2022-03-04 | TABUTEAU HERRIOT | Officer | A-Award | A | Restricted Stock Units | 110,861 | 0.00 | — | 110,861 | — | ↗ |
| 2022-03-04 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 2,337 | 0.00 | — | 2,337 | — | ↗ |
| 2022-03-04 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 77,872 | 0.00 | — | 77,872 | — | ↗ |
| 2022-03-04 | Jacobson Mark L. | Officer | A-Award | A | Restricted Stock Units | 47,990 | 0.00 | — | 47,990 | — | ↗ |
| 2022-03-04 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 2,347 | 0.00 | — | 2,347 | — | ↗ |
| 2022-03-04 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 2,798 | 0.00 | — | 2,798 | — | ↗ |
| 2021-11-19 | JEFFS ROGER | Director | P-Purchase | A | Common Stock | 3,950 | 37.30 | 147.4K | 120,756 | — | ↗ |
| 2021-11-18 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 527 | 35.50 | 18.7K | 41,789 | — | ↗ |
| 2021-11-18 | Coleman Mark | Director | P-Purchase | A | Common Stock | 1,021 | 35.10 | 35.8K | 422,428 | — | ↗ |
| 2021-11-17 | Saad Mark E | Director | P-Purchase | A | Common Stock | 3,000 | 34.53 | 103.6K | 10,002 | — | ↗ |
| 2021-11-12 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 36,086 | 39.26 | 1.42M | 36,086 | — | ↗ |
| 2021-11-12 | Jacobson Mark L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 41,638 | 39.26 | 1.63M | 41,638 | — | ↗ |
| 2021-06-04 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 7,325 | 61.32 | 449.2K | 7,325 | — | ↗ |
| 2021-06-04 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 7,325 | 61.32 | 449.2K | 7,325 | — | ↗ |
| 2021-06-04 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 7,325 | 61.32 | 449.2K | 7,325 | — | ↗ |
| 2021-05-12 | Coleman Mark | Director | P-Purchase | A | Common Stock | 500 | 58.15 | 29.1K | 420,998 | — | ↗ |
| 2021-03-05 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 97,155 | 65.02 | 6.32M | 97,155 | — | ↗ |
| 2021-03-05 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 1,241 | 65.02 | 80.7K | 1,241 | — | ↗ |
| 2021-03-05 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 36,086 | 65.02 | 2.35M | 36,086 | — | ↗ |
| 2021-03-05 | Jacobson Mark L. | Officer | A-Award | A | Restricted Stock Units | 22,163 | 0.00 | — | 22,163 | — | ↗ |
| 2021-03-05 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 1,463 | 65.02 | 95.1K | 1,463 | — | ↗ |
| 2021-03-05 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 1,201 | 65.02 | 78.1K | 1,201 | — | ↗ |
| 2020-08-19 | Coleman Mark | Director | G-Gift | D | Common Stock | 397,998 | 0.00 | — | 5,700 | — | ↗ |
| 2020-06-29 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 777 | 76.64 | 59.5K | 41,217 | — | ↗ |
| 2020-06-29 | Coleman Mark | Director | P-Purchase | A | Common Stock | 650 | 78.50 | 51.0K | 403,698 | — | ↗ |
| 2020-06-05 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 77.38 | 1.01M | 13,000 | — | ↗ |
| 2020-06-05 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 77.38 | 1.01M | 13,000 | — | ↗ |
| 2020-06-05 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 77.38 | 1.01M | 13,000 | — | ↗ |
| 2020-03-17 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 168,776 | 45.14 | 7.62M | 168,776 | — | ↗ |
| 2020-03-17 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 3,789 | 45.14 | 171.0K | 3,789 | — | ↗ |
| 2020-03-17 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 48,237 | 45.14 | 2.18M | 48,237 | — | ↗ |
| 2020-03-17 | Marek David C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 53,984 | 45.14 | 2.44M | 53,984 | — | ↗ |
| 2020-03-17 | Jacobson Mark L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,880 | 45.14 | 2.75M | 60,880 | — | ↗ |
| 2020-03-17 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 4,496 | 45.14 | 202.9K | 4,496 | — | ↗ |
| 2020-03-17 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 3,308 | 45.14 | 149.3K | 3,308 | — | ↗ |
| 2020-02-28 | Jacobson Mark L. | Officer | — | D | Stock Option (Right to Buy) | 40,673 | 6.47 | 263.2K | 0 | — | ↗ |
| 2020-01-10 | JEFFS ROGER | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,193 | 8.02 | 41.6K | 0 | — | ↗ |
| 2019-10-10 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 68,837 | 17.61 | 1.21M | 68,837 | — | ↗ |
| 2019-10-10 | Pizzie Nick | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,813 | 17.61 | 454.6K | 25,813 | — | ↗ |
| 2019-10-10 | Marek David C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,813 | 17.61 | 454.6K | 25,813 | — | ↗ |
| 2019-09-26 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 2,180 | 24.80 | 54.1K | 40,440 | — | ↗ |
| 2019-09-04 | Marek David C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 24.28 | 3.04M | 125,000 | — | ↗ |
| 2019-07-03 | JEFFS ROGER | Director | M-Exempt | A | Common Stock | 3,672 | 3.67 | 13.5K | 3,672 | — | ↗ |
| 2019-06-26 | Coleman Mark | Director | P-Purchase | A | Common Stock | 15,800 | 23.10 | 365.0K | 668,848 | — | ↗ |
| 2019-06-25 | Coleman Mark | Director | P-Purchase | A | Common Stock | 400 | 23.25 | 9.3K | 653,048 | — | ↗ |
| 2019-06-11 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 1,920 | 20.80 | 39.9K | 1,920 | — | ↗ |
| 2019-06-07 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 22.03 | 286.4K | 13,000 | — | ↗ |
| 2019-06-07 | POTTER MYRTLE S | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 22.03 | 286.4K | 13,000 | — | ↗ |
| 2019-06-07 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 22.03 | 286.4K | 13,000 | — | ↗ |
| 2019-06-07 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 22.03 | 286.4K | 13,000 | — | ↗ |
| 2019-05-23 | Saad Mark E | Director | P-Purchase | A | Common Stock | 3,500 | 22.33 | 78.2K | 7,002 | — | ↗ |
| 2019-05-13 | Coleman Mark | Director | P-Purchase | A | Common Stock | 4,650 | 21.44 | 99.7K | 652,648 | — | ↗ |
| 2019-03-19 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 319,212 | 12.95 | 4.13M | 319,212 | — | ↗ |
| 2019-03-19 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 29,387 | 12.95 | 380.6K | 29,387 | — | ↗ |
| 2019-03-19 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 5,340 | 12.58 | 67.2K | 36,340 | — | ↗ |
| 2019-03-19 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 34,866 | 12.95 | 451.5K | 34,866 | — | ↗ |
| 2019-03-19 | Coleman Mark | Director | P-Purchase | A | Common Stock | 5,100 | 12.18 | 62.1K | 5,100 | — | ↗ |
| 2018-06-19 | Pizzie Nick | Officer | P-Purchase | A | Common Stock | 30,600 | 3.10 | 94.9K | 31,000 | — | ↗ |
| 2018-06-01 | Saad Mark E | Director | A-Award | A | Stock Options (right to buy) | 13,000 | 3.45 | 44.9K | 13,000 | — | ↗ |
| 2018-06-01 | POTTER MYRTLE S | Director | A-Award | A | Stock Options (right to buy) | 13,000 | 3.45 | 44.9K | 13,000 | — | ↗ |
| 2018-06-01 | JEFFS ROGER | Director | A-Award | A | Stock Options (right to buy) | 13,000 | 3.45 | 44.9K | 13,000 | — | ↗ |
| 2018-06-01 | Coleman Mark | Director | A-Award | A | Stock Options (right to buy) | 13,000 | 3.45 | 44.9K | 13,000 | — | ↗ |
| 2018-05-16 | Pizzie Nick | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-12 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 187,628 | 2.85 | 534.7K | 187,628 | — | ↗ |
| 2018-03-12 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 32,602 | 2.85 | 92.9K | 32,602 | — | ↗ |
| 2018-03-12 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 39,948 | 2.85 | 113.9K | 39,948 | — | ↗ |
| 2018-03-12 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 27,297 | 2.85 | 77.8K | 27,297 | — | ↗ |
| 2017-08-04 | Golubieski John | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 132,000 | 5.90 | 778.8K | 132,000 | — | ↗ |
| 2017-06-16 | POTTER MYRTLE S | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 4.10 | 90.2K | 22,000 | — | ↗ |
| 2017-03-29 | JEFFS ROGER | Director | M-Exempt | A | Common Stock | 7,344 | 3.67 | 27.0K | 11,718 | — | ↗ |
| 2017-03-15 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 149,000 | 4.95 | 737.6K | 149,000 | — | ↗ |
| 2017-03-15 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 31,346 | 4.95 | 155.2K | 31,346 | — | ↗ |
| 2017-03-15 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 35,194 | 4.95 | 174.2K | 35,194 | — | ↗ |
| 2017-03-15 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 26,456 | 4.95 | 131.0K | 26,456 | — | ↗ |
| 2017-03-15 | Ames Constance | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 4.95 | 123.8K | 25,000 | — | ↗ |
| 2016-05-27 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 524,000 | 8.02 | 4.20M | 524,000 | — | ↗ |
| 2016-05-27 | Saad Mark E | Director | A-Award | A | Stock Option (Right to Buy) | 6,231 | 8.02 | 50.0K | 6,231 | — | ↗ |
| 2016-05-27 | JEFFS ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 5,193 | 8.02 | 41.6K | 5,193 | — | ↗ |
| 2016-05-27 | Coleman Mark | Director | A-Award | A | Stock Option (Right to Buy) | 5,193 | 8.02 | 41.6K | 5,193 | — | ↗ |
| 2016-05-27 | Ames Constance | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 8.02 | 200.5K | 25,000 | — | ↗ |
| 2015-12-23 | Kaye Randall | Officer | P-Purchase | A | Common Stock | 1,000 | 9.03 | 9.0K | 6,022 | — | ↗ |
| 2015-11-24 | TABUTEAU HERRIOT | Director / Officer / 10% Owner | A-Award | A | 8% Convertible Note | 7,229 | 5.94 | 42.9K | 0 | — | ↗ |
| 2015-11-24 | Saad Mark E | Director | A-Award | A | 8% Convertible Note | 3,502 | 5.94 | 20.8K | 0 | — | ↗ |
| 2015-11-24 | Kaye Randall | Officer | A-Award | A | 8% Convertible Note | 5,022 | 5.40 | 27.1K | 0 | — | ↗ |
| 2015-11-24 | JEFFS ROGER | Director | A-Award | A | 8% Convertible Note | 4,374 | 5.94 | 26.0K | 0 | — | ↗ |
| 2015-11-24 | Coleman Mark | Director | A-Award | A | 8% Convertible Note | 140,672 | 5.94 | 835.6K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-248.8K
Shares Outstanding
51.15M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 835.0K | — | 5.53M | 2.83M | 876.8K | 205.0K | 10.28M | 81.36% | ↗ |
| 2 | 2025 | Mark Jacobson, M.A. Chief Operating Officer | 575.0K | — | 2.08M | 1.07M | 388.0K | 95.6K | 4.21M | 74.84% | ↗ |
| 3 | 2025 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 530.0K | — | 1.82M | 933.3K | 358.0K | 86.6K | 3.73M | 73.88% | ↗ |
| 4 | 2025 | Hunter Murdock, Esq. General Counsel | 530.0K | — | 1.50M | 766.6K | 358.0K | 72.6K | 3.22M | 70.21% | ↗ |
| 5 | 2025 | Ari Maizel, M.B.A. Chief Commercial Officer | 530.0K | — | 1.50M | 766.6K | 358.0K | 37.0K | 3.19M | 70.99% | ↗ |
| 6 | 2024 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 780.0K | — | 2.83M | 5.67M | 955.5K | 129.4K | 10.36M | 82.01% | ↗ |
| 7 | 2024 | Mark Jacobson, M.A. Chief Operating Officer | 552.0K | — | 1.07M | 2.13M | 435.0K | 59.0K | 4.25M | 75.36% | ↗ |
| 8 | 2024 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 505.0K | — | 933.3K | 1.87M | 398.0K | 53.5K | 3.76M | 74.54% | ↗ |
| 9 | 2024 | Hunter Murdock, Esq. General Counsel | 505.0K | — | 766.5K | 1.53M | 398.0K | 42.7K | 3.25M | 70.86% | ↗ |
| 10 | 2024 | Ari Maizel, M.B.A. Chief Commercial Officer | 510.0K | — | 766.5K | 1.53M | 372.0K | 16.7K | 3.20M | 71.90% | ↗ |
| 11 | 2023 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 750.0K | — | 2.83M | 5.67M | 562.5K | 83.0K | 9.90M | 85.90% | ↗ |
| 12 | 2023 | Mark Jacobson, M.A. Chief Operating Officer | 530.0K | — | 1.07M | 2.13M | 265.0K | 40.8K | 4.04M | 79.29% | ↗ |
| 13 | 2023 | Ari Maizel, M.B.A. Chief Commercial Officer | 445.0K | — | 1.08M | 2.15M | 250.0K | — | 3.92M | 82.27% | ↗ |
| 14 | 2023 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 485.0K | — | 933.7K | 1.87M | 243.0K | 37.5K | 3.57M | 78.53% | ↗ |
| 15 | 2023 | Hunter Murdock, Esq. General Counsel | 485.0K | — | 766.9K | 1.53M | 243.0K | 29.3K | 3.06M | 75.23% | ↗ |
| 16 | 2022 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 685.0K | — | 2.31M | 4.69M | 616.5K | 19.5K | 8.32M | 84.13% | ↗ |
| 17 | 2022 | Mark Jacobson, M.A. Chief Operating Officer | 483.0K | — | 1.00M | 2.00M | 289.8K | 11.9K | 3.79M | 79.27% | ↗ |
| 18 | 2022 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 451.0K | — | 858.5K | 1.74M | 270.6K | 11.3K | 3.33M | 78.01% | ↗ |
| 19 | 2022 | Hunter Murdock, Esq. General Counsel | 450.0K | — | 577.5K | 1.17M | 270.0K | 15.4K | 2.48M | 70.40% | ↗ |
| 20 | 2021 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 685.0K | — | 2.33M | 4.67M | 349.4K | 20.7K | 8.05M | 86.90% | ↗ |
| 21 | 2021 | Mark Jacobson, M.A. Chief Operating Officer | 409.0K | — | 999.9K | 3.24M | 139.1K | 6.7K | 4.79M | 88.43% | ↗ |
| 22 | 2021 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 409.0K | — | 866.6K | 2.81M | 139.1K | 5.9K | 4.23M | 86.90% | ↗ |
| 23 | 2021 | Hunter Murdock, Esq. General Counsel | 350.0K | — | 6.4K | 12.8K | 5.2K | — | 374.4K | 5.13% | ↗ |
| 24 | 2020 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 575.0K | — | 1.62M | 4.67M | 448.5K | — | 7.30M | 85.99% | ↗ |
| 25 | 2020 | Mark Jacobson, M.A. Chief Operating Officer | 375.0K | — | 461.6K | 1.33M | 195.0K | — | 2.37M | 75.90% | ↗ |
| 26 | 2020 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 375.0K | — | 461.6K | 1.33M | 195.0K | — | 2.37M | 75.90% | ↗ |
| 27 | 2020 | David Marek Former Chief Commercial Officer | — | — | 392.4K | — | — | 544.4K | 936.8K | 41.89% | ↗ |
| 28 | 2019 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 435.0K | — | — | 3.95M | 326.3K | — | 4.72M | 83.86% | ↗ |
| 29 | 2019 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 435.0K | — | — | 3.95M | 326.3K | — | 4.72M | 83.86% | ↗ |
| 30 | 2019 | David Marek Chief Commercial Officer | 128.3K | 65.0K | — | 2.55M | 231.0K | — | 2.97M | 85.71% | ↗ |
| 31 | 2019 | Mark Jacobson, M.A. Chief Operating Officer | 310.0K | — | — | 1.48M | 162.8K | — | 1.96M | 75.83% | ↗ |
| 32 | 2019 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | 325.0K | — | — | 1.05M | 195.0K | — | 1.57M | 66.88% | ↗ |
| 33 | 2019 | David Marek Former Chief Commercial Officer | — | 65.0K | — | — | — | — | 65.0K | 0.00% | ↗ |
| 34 | 2018 | Herriot Tabuteau, M.D. Chief Executive Officer, President and Chairman of the Board | 435.0K | — | — | 361.4K | 261.0K | — | 1.06M | 34.18% | ↗ |
| 35 | 2018 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 435.0K | — | — | 361.4K | 261.0K | — | 1.06M | 34.18% | ↗ |
| 36 | 2018 | Nick Pizzie, CPA, M.B.A. Chief Financial Officer | 203.1K | 15.0K | — | 313.9K | 156.0K | — | 688.0K | 45.62% | ↗ |
| 37 | 2018 | John Golubieski Former Chief Financial Officer | 115.8K | — | — | — | — | — | 65.8K | 0.00% | ↗ |
| 38 | 2018 | Nick Pizzie, C.P.A., M.B.A. Chief Financial Officer | — | 15.0K | — | — | — | — | 15.0K | 0.00% | ↗ |
| 39 | 2017 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 435.0K | — | — | 488.3K | 200.1K | — | 1.12M | 43.46% | ↗ |
| 40 | 2017 | John Golubieski Former Chief Financial Officer | 131.9K | 50.0K | — | 519.6K | 49.0K | — | 750.4K | 69.24% | ↗ |
| 41 | 2017 | John Golubieski Chief Financial Officer | 131.9K | 50.0K | — | 519.6K | 49.0K | — | 750.4K | 69.24% | ↗ |
| 42 | 2017 | Constance Ames Former Vice President, Finance and Treasurer | 179.7K | — | — | 81.9K | — | — | 261.6K | 31.31% | ↗ |
| 43 | 2016 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 435.0K | — | — | 2.76M | 174.0K | — | 3.36M | 81.90% | ↗ |
| 44 | 2016 | Constance Ames Vice President, Finance and Treasurer | 225.0K | 53.3K | — | 131.4K | — | — | 409.8K | 32.08% | ↗ |
| 45 | 2016 | Constance Ames Former Vice President, Finance and Treasurer | 225.0K | — | — | 131.4K | 53.3K | — | 409.8K | 32.08% | ↗ |
| 46 | 2016 | Randall Kaye, M.D. Former Chief Medical Officer | 273.3K | — | — | — | — | — | 273.3K | 0.00% | ↗ |
| 47 | 2015 | Randall Kaye, M.D. Chief Medical Officer | 126.7K | 50.8K | — | 527.6K | — | — | 705.1K | 74.83% | ↗ |
| 48 | 2015 | Randall Kaye, M.D. Former Chief Medical Officer | 126.7K | 50.8K | — | 527.6K | — | — | 705.1K | 74.83% | ↗ |
| 49 | 2015 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 300.0K | 150.0K | — | — | — | — | 450.0K | 0.00% | ↗ |
| 50 | 2015 | Constance Ames Vice President, Finance and Treasurer | 175.0K | 52.4K | — | 161.6K | — | — | 389.1K | 41.55% | ↗ |
| 51 | 2014 | Herriot Tabuteau, M.D. Chief Executive Officer and Chairman of the Board | 250.0K | 125.0K | — | — | — | — | 375.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Herriot Tabuteau | Founder, Chairman, Chief Executive Officer & President | 2M | — |
| Mark L. Jacobson | Chief Operating Officer | 1M | male |
| Hunter Murdock | General Counsel & Secretary | 960.6K | male |
| Nick Pizzie | Chief Financial Officer | 956.5K | male |
| Ari Maizel | Chief Commercial Officer | 925.0K | male |
| Darren Opland | Director of Corporate Communications | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AXSM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
